MLAB logo

Mesa Laboratories, Inc. Stock Price

NasdaqGS:MLAB Community·US$375.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

MLAB Share Price Performance

US$70.75
-53.67 (-43.14%)
US$70.75
-53.67 (-43.14%)
Price US$70.75

MLAB Community Narratives

There are no narratives available yet.

Recent MLAB News & Updates

Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16

Oct 06
Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16

Mesa Laboratories (NASDAQ:MLAB) Is Paying Out A Dividend Of $0.16

Aug 20
Mesa Laboratories (NASDAQ:MLAB) Is Paying Out A Dividend Of $0.16

It's Down 27% But Mesa Laboratories, Inc. (NASDAQ:MLAB) Could Be Riskier Than It Looks

Jul 20
It's Down 27% But Mesa Laboratories, Inc. (NASDAQ:MLAB) Could Be Riskier Than It Looks

Mesa Laboratories (NASDAQ:MLAB) Is Due To Pay A Dividend Of $0.16

Jul 15
Mesa Laboratories (NASDAQ:MLAB) Is Due To Pay A Dividend Of $0.16

Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Intrinsic Value Is Potentially 32% Above Its Share Price

Jul 07
Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Intrinsic Value Is Potentially 32% Above Its Share Price

Mesa Laboratories, Inc. Key Details

US$242.4m

Revenue

US$91.3m

Cost of Revenue

US$151.0m

Gross Profit

US$151.6m

Other Expenses

-US$620.0k

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
-0.11
Gross Margin
62.31%
Net Profit Margin
-0.26%
Debt/Equity Ratio
105.0%

Mesa Laboratories, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards

About MLAB

Founded
1982
Employees
730
CEO
Gary Owens
WebsiteView website
www.mesalabs.com

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.8%
  • 3 Months: 8.3%
  • 1 Year: 17.8%
  • Year to Date: 15.4%
Over the last 7 days, the market has remained flat, although notably the Utilities sector gained 3.1% in that time. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›